HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

caspofungin (Cancidas)

Subscribe to New Research on caspofungin

a cyclic hexapeptide echinocandin

Also Known As:

Cancidas; caspofungin acetate; Caspofungin MSD; L 743,872; L 743872; L-743,872; L-743872; MK 0991; MK-0991; MSD brand of caspofungin acetate; Merck Frosst brand of caspofungin acetate; Merck Sharp & Dohme brand of caspofungin acetate; Merck brand of caspofungin acetate

Networked: 765 relevant articles (137 outcomes, 127 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Peptides: 22950
  - Cyclic Peptides: 55
    - Echinocandins: 324
      - caspofungin: 765

Experts

1.	Kontoyiannis, Dimitrios P: 18 articles (11/2015 - 07/2003)
2.	Kartsonis, Nicholas A: 16 articles (06/2015 - 09/2002)
3.	Cornely, Oliver A: 15 articles (01/2015 - 09/2004)
4.	Lewis, Russell E: 14 articles (11/2014 - 07/2003)
5.	Walsh, Thomas J: 12 articles (12/2012 - 01/2002)
6.	Sable, Carole A: 11 articles (09/2007 - 02/2002)
7.	Maertens, Johan: 9 articles (01/2012 - 06/2003)
8.	Najvar, Laura K: 8 articles (02/2015 - 07/2003)
9.	Wiederhold, Nathan P: 8 articles (02/2015 - 08/2003)
10.	Fothergill, Annette W: 8 articles (02/2015 - 09/2002)

Related Diseases

1.	Infection 01/01/2011 - "The recently introduced caspofungin (CPF) offers an excellent safety profile, but underperformed in terms of efficacy against mold infections. " 12/01/2010 - "Caspofungin was found to be an effective treatment of probable and proven invasive fungal infections in patients following SOT in Germany." 04/01/2008 - "The therapeutic efficacy of caspofungin in relation to the severity of invasive pulmonary infection caused by Aspergillus fumigatus in transiently neutropenic rats was investigated by using rat survival and the decrease in the fungal burden as the parameters of efficacy. " 12/01/2012 - "In routine clinical practice conditions, caspofungin is effective and safe for the treatment of invasive fungal infections (IC/IA). " 09/01/2013 - "In a murine model of disseminated infection, we evaluated the efficacy of caspofungin at 5 mg/kg against 8 strains of C. "
2.	Aspergillosis 01/01/2007 - "We analyzed retrospectively the safety and efficacy of caspofungin-based combination therapy in 40 children and adolescents, most of them were being treated for a malignant disease, who developed invasive aspergillosis (IA) between November 2002 and November 2005. " 01/01/2007 - "Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients." 11/01/2005 - "Caspofungin, a new antifungal agent with proven efficacy against invasive aspergillosis, has ideal potential for aerosolization. " 08/01/2001 - "Caspofungin was effective in patients with invasive aspergillosis intolerant or refractory to standard therapies. " 01/01/2013 - "Evidence supporting a role for mammalian chitinases in efficacy of caspofungin against experimental aspergillosis in immunocompromised rats."
3.	Invasive Candidiasis 07/01/2011 - "We hypothesized that higher doses of caspofungin would be effective against invasive candidiasis caused by the more virulent species Candida albicans, including isolates resistant to this echinocandin. " 07/01/2011 - "These data suggest that caspofungin dose escalation for invasive candidiasis may not be consistently effective against resistant C. " 01/01/2007 - "Caspofungin is a new antifungal agent effective in the treatment of invasive candidiasis. " 08/01/2007 - "Caspofungin has demonstrated efficacy in invasive candidiasis. " 08/01/2010 - "A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients."
4.	Candidiasis (Moniliasis) 01/01/2001 - "Caspofungin was effective in patients with oropharyngeal or oesophageal candidiasis, according to the preliminary results of 2 randomised double-blind trials. " 07/01/2011 - "Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis." 04/01/2011 - "Efficacy of a single 6 mg/kg versus two 3 mg/kg caspofungin doses for treatment of disseminated candidiasis caused by Candida albicans in a neutropenic mouse model." 02/01/2002 - "Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study." 08/15/2013 - "Paradoxical effect to caspofungin in Candida species does not confer survival advantage in a Drosophila model of candidiasis."
5.	Candidemia 03/01/2004 - "The addition of caspofungin resulted in rapid clearance of the candidemia. " 01/01/2014 - "Secondary antifungal prophylaxis with caspofungin was found effective in treating six FN episodes in three patients who had experienced at least two persistent candidemia attacks. " 05/01/2011 - "In the analyzed period, among 307 children who underwent surgical procedures, we observed 2 cases of candidemia (0.65%) which were effectively cured with caspofungin. " 03/01/2014 - "Caspofungin successfully treated persistent candidemia in extremely premature infants at 23 and 24 weeks' gestational age." 03/01/2014 - "There was no recurrent candidemia after discontinuing caspofungin. "

Related Drugs and Biologics

1.	Amphotericin B (Amphotericin)
2.	voriconazole (Vfend)
3.	liposomal amphotericin B
4.	Fluconazole (Zonal)
5.	micafungin (FK463)
6.	Antifungal Agents
7.	anidulafungin
8.	posaconazole
9.	Echinocandins
10.	Itraconazole (Sporanox)

Related Therapies and Procedures

1.	Salvage Therapy
2.	Transplants (Transplant)
3.	Drug Therapy (Chemotherapy)
4.	Stem Cell Transplantation
5.	Catheters